Daily Updates
Trump Is Coming for Generic Drug Imports With 2028 Tariffs
Two weeks ago we covered the White House pressing pharma executives to bring generic manufacturing home, and our read was blunt: expect supportive statements and
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Two weeks ago we covered the White House pressing pharma executives to bring generic manufacturing home, and our read was blunt: expect supportive statements and
The GLP 1 fight just added a courtroom. Novo Nordisk sued Lilly in federal court, accusing its rival of misleading advertising around their obesity and
Quieter news day, so it is a good moment to step back and appreciate what Lilly is doing, because the scale of it is genuinely
Two weeks ago, Vera Therapeutics beat Vertex to market as the first dual BAFF and APRIL inhibitor approved for IgA nephropathy. We flagged it as
Two things worth your attention this morning, and they could not be more different. The first is Lilly doing what Lilly does. The company agreed
Biogen gave the Alzheimer’s field something real to argue about this week, and the argument is worth having. At the Alzheimer’s Association International Conference, the
Yesterday we said to watch what companies do rather than what they say about China, and pointed to AstraZeneca as the tell. Today AstraZeneca made
Washington is running two China strategies at once, and this is the week they collide. Operation TrialBlazer is the carrot—an HHS initiative to win clinical
AstraZeneca does not miss often, which is what makes the Wainua failure worth sitting with. The drug, developed with Ionis, is a gene silencer designed
On Monday we set the week’s question: would the industry keep signing China deals into the teeth of the congressional probe, with the July 17